AMIX Autonomix Medical, Inc.

Nasdaq autonomix.com


$ 1.11 $ 0.00 (0 %)    

Tuesday, 21-Oct-2025 07:40:07 EDT
QQQ $ 611.74 $ 0.00 (0 %)
DIA $ 467.33 $ 0.00 (0 %)
SPY $ 671.61 $ 0.00 (0 %)
TLT $ 91.66 $ 0.00 (0 %)
GLD $ 388.84 $ 0.00 (0 %)
$ 1.13
$ 1.11
$ 1.10 x 35
$ 1.15 x 2,029
-- - --
$ 0.96 - $ 21.49
143,191
na
5.81M
$ -0.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-29-2025 03-31-2025 10-K
3 02-13-2025 12-31-2024 10-Q
4 11-08-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-31-2024 03-31-2024 10-K
7 02-13-2024 12-31-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

 With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sens...

Core News & Articles

GLP study marks a key milestone in Autonomix's path to achieve regulatory approvalsCompany remains on track to submit Inves...

Core News & Articles

New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a ...

Core News & Articles

On August 25, 2025, Autonomix Medical, Inc. (the "Company") entered into a purchase agreement, dated as of August 25, 2...

Core News & Articles

Global patent estate encompasses 80 issued patents and 40 pending patent applicationsStrengthens strategic position in a multi-...

Core News & Articles

Autonomix Medical (NASDAQ:AMIX) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1...

Core News & Articles

Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to adv...

Core News & Articles

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sen...

Core News & Articles

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer painPoC 2 phas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION